• Please log in or register to access this feature.

Short Report

Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers

  1. Y Liu1,
  2. TI Winarni2,
  3. L Zhang3,
  4. F Tassone4,5,
  5. RJ Hagerman5,*

Article first published online: 17 OCT 2012

DOI: 10.1111/cge.12026

Additional Information

How to Cite

Liu Y, Winarni TI, Zhang L, Tassone F, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers.

Author Information

  1. 1

    Department of Neurology, Dalian Municipal Friendship Hospital, Dalian, PR China

  2. 2

    Center for Biomedical Research, Faculty of Medicine Diponegoro University, Semarang, Central Java, Indonesia

  3. 3

    Department of Neurology, University of California Davis School of Medicine, Sacramento, CA, USA

  4. 4

    Department of Biochemistry and Molecular Medicine, University of California Davis School of Medicine, Sacramento, CA, USA

  5. 5

    MIND Institute, University of California Davis School of Medicine, Sacramento, CA, USA

* Corresponding author: Randi J. Hagerman MD, MIND Institute, University of California Davis Health System, 2825 50th Street, Sacramento, CA, 95817, USA
Tel.: +1 916 703-0247
Fax: +1 916 703-0240
e-mail: randi.hagerman@ucdmc.ucdavis.edu

  1. Dr Hagerman's work has been funded by the NIH. Other funding has been received for clinical trials from Seaside Therapeutics, Roche, Forest, Curemark, and Novartis. Dr. Zhang's work has been funded by the NIH. Other funding has been received for clinical trials from Boehringer-Ingelheim, and Allergan. Dr. Zhang serves as consultant and/or adviser for Allergan, Dysport, Teva Neuroscience, and Merz. Dr. Zhang serves as speaker for Allergan, Novartis, and Teva Neuroscience. Dr. Ying Liu's work has been funded by Teva Neuroscience and Allergan. There are no other conflicts of interest from the authors.

Publication History

  1. Article first published online: 17 OCT 2012
  2. Accepted manuscript online: 25 SEP 2012 10:37AM EST
  3. Manuscript Revised: 21 SEP 2012
  4. Manuscript Accepted: 21 SEP 2012
  5. Manuscript Received: 15 JUL 2012

Funded by

  • NIH. Grant Numbers: HD036071, HD02274
  • Neurotherapeutic Research Institute. Grant Numbers: DE019583, DA02484
  • National Institute on Aging. Grant Numbers: AG032119, AG032115
  • National Center for Research Resources. Grant Number: UL1 RR024146
  • The Health and Human Services Administration of Developmental Disabilities. Grant Number: 90DD05969

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (820K)

Options for accessing this content:

  • If you have access to this content through a society membership, please first log in to your society website.
  • If you would like institutional access to this content, please recommend the title to your librarian.
  • Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
  • You can purchase online access to this Article for a 24-hour period (price varies by title)
    • If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
    • New Users: Please register, then proceed to purchase the article.

If your institution is a registered Wiley Online Library customer, you can log in under your institution's name to see our content. This access is provided by Shibboleth or Athens.

Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions.

Please register to:

  • Save publications, articles and searches
  • Get email alerts
  • Get all the benefits mentioned below!

Register now >

View Full Article (HTML) Get PDF (820K)